TITLE

Does sex affect how patients respond to ASA?

AUTHOR(S)
Murray, Sally
PUB. DATE
March 2006
SOURCE
CMAJ: Canadian Medical Association Journal;3/14/2006, Vol. 174 Issue 6, p770
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The role of ASA in the primary prevention of cardiovascular disease is unclear, in particular whether women and men derive the same benefit from taking it. This meta-analysis was designed to assess the impact of sex on response to ASA for the primary prevention of cardiovascular events. Design: Prospective randomized controlled trials of ASA therapy for patients without cardiovascular disease reporting on myocardial infarct (MI), stroke and cardiovascular death were identified for the meta-analysis. Results: Six trials were identified with a total of 95 456 participants (of which 51 342 were women and 44 144 were men). Three included only men, 1 included only women and 2 included both sexes. The weighted mean duration of follow-up was 6.4 years. Table 1 shows key findings from the meta-analysis. Among participants taking ASA, major cardiovascular events -- defined as nonfatal MI, nonfatal stroke or cardiovascular death -- were reduced in both sexes in all of the trials, although there was no reduction in all-cause death for either men or women. Other clinical outcomes showed different results for men and women. The risk of stroke was reduced among women, but this reduction was related mainly to ischemic stroke (odds ratio [OR] 0.76, 95% confidence interval [CI] 0.63-0.93); there was no effect on hemorrhagic stroke. For men, there was no overall effect on stroke (OR 1.00, 95% CI 0.96-1.33), including ischemic stroke; however, the risk of hemorrhagic stroke was increased by 69% (OR 1.69, 95% CI 1.04-2.73). The risk of MI was reduced among men but not among women. Major bleeding was associated with ASA therapy in both women and men and usually occurred in the gastrointestinal tract. Commentary: The findings of this meta-analysis show important sex-related differences in the effect of ASA on the primary prevention of cardiovascular events. Although ASA therapy reduces the overall risk of cardiovascular events in both sexes, the reduction takes a different form in each sex: the risk of ischemic stroke is reduced among women and the risk of MI reduced among men. Sex-related differences in response to ASA have recently been identified. The Women's Health Study, the first primary prevention trial of ASA therapy specific to women, also found that the risk of stroke was decreased but not that of MI or cardiovascular death. Similarly, the Hypertension Optimal Therapy trial, which involved men and women with hypertension, found no effect on MI in women (although there was a significant benefit for men). Berger and colleagues present several possible explanations for these differences, including differing ASA metabolism in women and men and increased ASA resistance in women (e.g., ASA does not produce an anticipated effect, such as inhibiting biosynthesis of thromboxane or platelet aggregation). Event rates for stroke and MI are also different between the sexes, and it is possible that small numbers of these events in the trials meant that it was not possible to detect statistically significant benefits of ASA therapy for MI in women and stroke in men. Practice implications: The benefits of ASA therapy need to be weighed against the risk of major bleeding. Although ASA therapy for 6.4 years may prevent 2 strokes per 1000 women and 8 MIs per 1000 men, in the same period 2.5 and 3 major bleeding events per 1000 women and men respectively would occur. Also, because different doses and treatment durations were used in the trials, no firm recommendation regarding doses for primary prevention can be derived. However, current guidelines recommend 75-162 mg/day for primary prevention for both men and women.
ACCESSION #
20037723

 

Related Articles

  • Aspirin appears to protect men and women differently. Chambers, Christopher V.; Russell, John J. // Patient Care;May2005, Vol. 39 Issue 5, p65 

    Provides information on a randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Primary outcome of the trial; Comparison between the aspirin group and the placebo group; Effect of low-dose aspirin on stroke risk in women.

  • Take an Aspirin and ... Buring, Julie; Ferrari, Nancy // Newsweek;4/24/2006, Vol. 147 Issue 17, p71 

    The article presents information about the benefits and risks of aspirin. The authors suggest that aspirin might help prevent clot-related cardiovascular events such as heart attack and stroke in both men and women. The authors note that while aspirin may reduce the chances of a recurrent...

  • Low-dose aspirin lowered stroke risk but not risk for MI or cardiovascular death in women.  // ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p33 

    The article presents an answer to a clinical question related to the effectiveness of low-dose aspirin for the primary prevention of cardiovascular disease in women. Women receiving aspirin and those receiving placebo did not differ for rates of a first major cardiovascular event, death from...

  • Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women. Ridker, P. M.; Cook, N. R.; Lee, I. M.; Eikelboom, John W. // Evidence Based Medicine;Oct2005, Vol. 10 Issue 5, p137 

    The article discusses whether low dose aspirin is effective for the primary prevention of cardiovascular disease (CVD) in women. The Women's Health Study randomized almost 40,000 initially healthy women and, in contrast to previous trials, aspirin did not reduce myocardial infarction or death...

  • Drugs for Cardiovascular Disease Prevention in Women: Implications of the AHA Guidelines – 2007 Update. Wenger, Nanette K // Drugs;2008, Vol. 68 Issue 3, p339 

    Lifestyle interventions constitute the initial strategy for the primary and secondary prevention of cardiovascular disease in women. However, pharmacotherapy is often indicated for control of major cardiovascular risk factors, and abundant clinical trial data support the morbidity and mortality...

  • Aspirin in women cuts CVD deaths.  // Pulse;11/19/2005, Vol. 65 Issue 45, p12 

    The article reports that aspirin can cut death rates in postmenopausal women with cardiovascular disease.

  • Effects of Aspirin Differ for Men and Women.  // Access;Jul2005, Vol. 19 Issue 6, p12 

    Cites a study in the U.S. about the effects of low-dose aspirin therapy on women with different forms of cardiovascular disease. Number of major cardiovascular events for associated with the aspirin group; Risk reduction rate for all strokes; Prevalence of gastrointestinal bleeding requiring...

  • Waistline may be predictor for CVD. Haigh, Christen // Endocrine Today;10/25/2008, Vol. 6 Issue 19, p24 

    The article reports on the higher risk for cardiovascular disease of women with larger waistlines.

  • Without warning. Dortch, Irene Preston // Better Homes & Gardens;Sept2001, Vol. 79 Issue 9, p242 

    Focuses on the dangers and risks of heart diseases to women. Similarity of symptoms to those associated with men; Risk factors; Experiences of two women suffering from heart disease.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics